LONG-TERM USE OF CYCLOSPORINE IN LIVER RECIPIENTS
- 1 December 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 36 (6), 641-643
- https://doi.org/10.1097/00007890-198336060-00010
Abstract
Cyclosporine is a potent immunosuppressive drug, which has dose-related nephrotoxicity. In renal transplantation, the differentiation between rejection and toxicity is difficult and even with the aid of blood levels of the drug, it may be difficult to establish a chronic maintenance dose. Long-term survivors after liver transplantation can provide modes with which to establish maintenance doses, as these are dictated by nephrotoxicity in these patients. Twenty-nine liver transplant patients who survived one year or more were followed for changes in their cyclosporine doses. Daily oral cyclosporine dose, BUN, serum creatinine and bilirubin were monitored. The reductions in cyclosporine were dictated almost entirely by the findings of nephrotoxicity.This publication has 4 references indexed in Scilit:
- Evolution of Liver TransplantationHepatology, 1982
- NEPHROTOXICITY OF CYCLOSPORIN A IN LIVER AND KIDNEY TRANSPLANT PATIENTSThe Lancet, 1981
- THE USE OF CYCLOSPORIN-A AND PREDNISONE IN CADAVER KIDNEY-TRANSPLANTATION1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979